DexCom
DXCM
New Fortress Energy
NFE
Hutchmed (China)
HCM
4
Halozyme Therapeutics
HALO
5
YETI Holdings
YETI
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -34.57%3.38M | 56.39%-1.37M | -72.27%544K | -8.40%2.27M | -49.90%1.94M | 829.80%5.17M | -1,017.84%-3.14M | 298.78%1.96M | 295.89%2.48M | 222.06%3.87M |
Net income from continuing operations | -19.44%-3.51M | -300.00%-2.84M | 102.80%54K | 56.84%-615K | 89.10%-109K | -256.56%-2.94M | 206.37%1.42M | -248.56%-1.93M | -212.92%-1.43M | -139.97%-1M |
Operating gains losses | --1.06M | --0 | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Depreciation and amortization | 26.61%4.08M | 42.15%1.18M | 38.56%1.13M | 16.69%930K | 7.70%839K | 13.70%3.22M | 7.12%828K | -7.68%817K | 70.30%797K | 10.18%779K |
Deferred tax | 38.64%61K | ---96K | 6,800.00%134K | -13.64%19K | -83.33%4K | --44K | --0 | ---2K | --22K | --24K |
Other non cash items | -21.73%2.24M | 534.06%2.05M | -64.05%623K | -150.00%-187K | -156.48%-244K | 564.04%2.86M | 194.72%323K | 996.84%1.73M | -10.31%374K | 119.29%432K |
Change In working capital | -146.18%-532K | 72.67%-1.51M | -213.01%-1.44M | -57.74%978K | -53.36%1.45M | 157.11%1.15M | -1,411.85%-5.54M | 171.93%1.28M | 231.85%2.31M | 184.22%3.1M |
-Change in receivables | 142.45%1.85M | 113.48%868K | -399.84%-1.87M | -137.37%-105K | 150.81%2.95M | -10.98%-4.36M | -489.56%-6.44M | -48.17%622K | 190.35%281K | 131.61%1.18M |
-Change in inventory | 250.37%615K | 552.84%1.04M | 96.33%-43K | -41.67%119K | -163.20%-498K | -107.61%-409K | -127.43%-229K | -149.36%-1.17M | 133.22%204K | 1,415.38%788K |
-Change in prepaid assets | -120.38%-194K | -224.73%-116K | 225.57%221K | -735.00%-127K | -116.95%-172K | 98.33%952K | -75.72%93K | -119.38%-176K | 101.26%20K | 30.63%1.02M |
-Change in payables and accrued expense | -140.17%-1.78M | -111.32%-431K | -67.70%573K | 219.74%734K | -400.75%-2.66M | 119.10%4.44M | 121.45%3.81M | 173.61%1.77M | -257.58%-613K | -122.82%-531K |
-Change in other working capital | -293.18%-1.02M | -3.61%-2.87M | -243.86%-328K | -85.26%357K | 180.74%1.82M | 232.33%528K | -94.59%-2.77M | 122.75%228K | 556.37%2.42M | -60.86%649K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -34.57%3.38M | 56.39%-1.37M | -72.27%544K | -8.40%2.27M | -49.90%1.94M | 829.80%5.17M | -1,017.84%-3.14M | 298.78%1.96M | 295.89%2.48M | 222.06%3.87M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 30.44%-2.8M | 43.87%-499K | 13.69%-807K | 43.11%-665K | 19.73%-830K | 81.25%-4.03M | 26.35%-889K | -29.50%-935K | 25.87%-1.17M | 94.25%-1.03M |
Capital expenditure reported | 25.02%-2.79M | 42.87%-497K | 7.04%-806K | 32.42%-663K | 17.85%-824K | 10.12%-3.72M | 26.33%-870K | -37.40%-867K | 36.83%-981K | -29.42%-1M |
Net PPE purchase and sale | 96.41%-11K | 89.47%-2K | 98.53%-1K | 98.94%-2K | 80.65%-6K | -105.37%-306K | 26.92%-19K | 25.27%-68K | -754.55%-188K | -210.00%-31K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 30.44%-2.8M | 43.87%-499K | 13.69%-807K | 43.11%-665K | 19.73%-830K | 81.25%-4.03M | 26.35%-889K | -29.50%-935K | 25.87%-1.17M | 94.25%-1.03M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -1,890.51%-2.45M | 241.66%2.04M | -172.34%-2.96M | 78.64%-416K | -99.11%-1.12M | -99.35%137K | -185.65%-1.44M | 1,409.29%4.09M | -534.53%-1.95M | -102.83%-562K |
Net issuance payments of debt | 59.62%-2.15M | 242.84%2.05M | -108.33%-2.85M | 88.19%-230K | -99.11%-1.12M | -149.12%-5.32M | -185.65%-1.44M | -338.78%-1.37M | -534.53%-1.95M | -105.76%-562K |
Net common stock issuance | --0 | --0 | ---- | ---- | ---- | 200.66%5.45M | --0 | ---- | ---- | ---- |
Net other financing activities | ---306K | ---17K | ---103K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -1,890.51%-2.45M | 241.66%2.04M | -172.34%-2.96M | 78.64%-416K | -99.11%-1.12M | -99.35%137K | -185.65%-1.44M | 1,409.29%4.09M | -534.53%-1.95M | -102.83%-562K |
Net cash flow | ||||||||||
Beginning cash position | 78.20%2.91M | -89.64%868K | 25.18%4.09M | -25.76%2.9M | 78.20%2.91M | -43.36%1.63M | 922.71%8.38M | 14.93%3.26M | -34.79%3.91M | -43.36%1.63M |
Current changes in cash | -246.67%-1.87M | 103.09%169K | -162.95%-3.22M | 285.18%1.19M | -100.48%-11K | 202.16%1.28M | -771.50%-5.47M | 352.94%5.11M | 79.64%-641K | -26.83%2.27M |
End cash Position | -64.36%1.04M | -64.36%1.04M | -89.64%868K | 25.18%4.09M | -25.76%2.9M | 78.20%2.91M | 78.20%2.91M | 922.71%8.38M | 14.93%3.26M | -34.79%3.91M |
Free cash flow | -49.12%580K | 53.62%-1.87M | -125.61%-263K | 22.65%1.6M | -60.90%1.11M | 122.81%1.14M | -365.66%-4.03M | 160.09%1.03M | 146.04%1.31M | 581.25%2.83M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |